{"prompt": "['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 14 of 115', 'TIA', 'Transient ischemic attack', 'TTE', 'Transthoracic echocardiogram', 'TTM', 'Trans-telephonic monitoring', 'US', 'United States', 'UADE', 'Unanticipated adverse device effect', 'USADE', 'Unanticipated serious adverse device effect', '3. Sponsor Contacts', 'Regional contact information is provided below. This information may be subject to change during the course', 'of the study. Periodic updates to studycontact informationwill besenttocenters as needed.', 'Table 2: Study Sponsor Contact Information', 'Worldwide and US Clinical Study Leader', 'Study Contacts', 'Dana Wigert, Principal Clinical Research Specialist', 'Direct Phone: 763-526-2802', 'Direct Fax: 763-367-1727', 'Email: dana.wigert@medtronic.com', 'Europe', 'Daniel Becker, Senior Clinical Research Specialist', 'Direct Phone: 49 215981490', 'Direct Fax: 49 21598149100', 'Email: daniel.becker@medtronic.com', 'Canada', 'Mary McCann, Senior Clinical Research Specialist', 'Direct Phone: 905-460-3639', 'Direct Fax: 905-460-3998', 'Email: mary.mccann@medtronic.com', 'Japan', 'Yoshiko Ishiwatari, Senior Clinical Research Specialist', 'Direct Phone: 81-3 6776-0105', 'Direct Fax: 81-3 6774-4705 -', 'Email: yoshiko.ishiwatari@medtronic.com', 'US, Canada', 'Monitoring', 'Beth Ornell, Clinical Monitoring Manager', 'Contacts', 'Direct Phone: 508-261-8000', 'Email: beth.a.ornell@medtronic.com', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 15 of 115', 'Europe', 'Anja Hesse, Clinical Monitoring Manager', 'Direct Phone: 49215981490', 'Direct Fax: 4921027069069', 'Email: anja.hesse@medtronic.com', 'Japan', 'Shinya Yoshida, Senior Clinical Monitoring Manager', 'Direct Phone: 81-36776-0141', 'Direct Fax: 81-3 6774-4705', 'Email: shinya.yoshida@medtronic.com', '4. CROs/Core Laboratories', 'This information may be subject to change during the course of the clinical study. Periodic updates to', 'contact information will be sent to centers as needed.', 'Table 3: CRO and Core Laboratory Information', 'Contact Information', 'Duties performed', 'Cognizant Technology Solutions', 'Development of study electronic case report forms, edit', '500 Frank W. Burr Blvd.', 'checks, and study management reports.', 'Teaneck, NJ 07666', 'Review of electronic case report forms, management of', 'Direct Phone: (201) 801-0233', 'discrepancies, and coding of medications and deviations.', 'Direct Fax: (201) 801-0243', 'Holter, trans-telephonic monitors', 'Distribution of Holters, TTMs and 12-lead ECG machines', '(TTM) and 12-lead ECG Core', 'Adjudication of atrial arrhythmias', 'Laboratory', 'Contact provided under separate', 'cover', '5. Synopsis', 'Table 4: Study Synopsis', 'Title', 'STOP Persistent AF study', 'Clinical Study Type', 'Pivotal', 'Product Name', 'Arctic Front AdvanceTM Cardiac CryoAblation Catheter', 'Freezor MAX\u00ae Cardiac CryoAblation Catheter', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 16 of 115', 'United States of America', 'Sponsor', 'Medtronic, Inc.', '8200 Coral Sea Street NE', 'Mounds View, MN 55112', 'United States of America', 'Canada', 'Local Sponsor', 'Medtronic of Canada, Ltd.', '99 Hereford Street', 'Brampton, Ontario, L6Y OR3', 'Canada', 'Europe', 'Medtronic, Bakken Research Center B.V.', 'Endeplosdomein 5', '6229 GW Maastricht', 'The Netherlands', 'Japan', 'Medtronic Japan Co. Ltd.', '1-2-70 Konan', 'Minato-ku, Tokyo 108-0075', 'Japan', 'Indication under', 'The proposed indication for the Arctic Front Advance CryoAblation Catheter is as', 'investigation', 'follows: The Arctic Front Advance Cardiac CryoAblation Catheters are indicated for', 'the treatment of drug refractory recurrent symptomatic paroxysmal and persistent', 'atrial fibrillation.', 'The proposed indication for the Freezor MAX Cardiac CryoAblation Catheter is as', 'follows: The Freezor MAX Cardiac CryoAblation Catheters are indicated for use as an', 'adjunctive device in the endocardial treatment of paroxysmal and persistent atrial', 'fibrillation in conjunction with the Arctic Front Advance Cardiac CryoAblation', 'Catheter for the following uses: gap cryoablation to complete electrical isolation of', 'the pulmonary veins, cryoablation of focal trigger sites and creation of ablation line', 'between the inferior vena cava and the tricuspid valve.', 'These proposed indications are outside of the approved indications in the United', 'States and Japan but are within the approved indications in Europe and Canada.', 'Investigation', 'To demonstrate safety and effectiveness of the Arctic Front Advance and Freezor', 'Purpose', 'MAX Cardiac CryoAblation Catheters for the treatment of drug refractory recurrent', 'symptomatic persistent atrial fibrillation (AF).', 'Version 4, 10NOVO016', 'Confidential']\n\n###\n\n", "completion": "END"}